Published interim consolidated results (core basis) and consolidated earnings forecast for the fiscal year ending March 2027. Revenue is 455.0 hundred million yen, down 11.8% year-over-year; core operating income is 124.0 hundred million yen (down 9.6% year-over-year); core net income attributable to owners of parent is 93.0 hundred million yen (down 10.1% year-over-year). Product sales are expected to decline, while royalties and other revenue are expected to increase. Research and development investment will continue.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4528","jir_company_name":"Ono Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-29","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4528-20261029-02.pdf","jir_short_summary":"Published interim consolidated results (core basis) and consolidated earnings forecast for the fiscal year ending March 2027. Revenue is 455.0 hundred million yen, down 11.8% year-over-year; core operating income is 124.0 hundred million yen (down 9.6% year-over-year); core net income attributable to owners of parent is 93.0 hundred million yen (down 10.1% year-over-year). Product sales are expected to decline, while royalties and other revenue are expected to increase. Research and development investment will continue.","jir_summary":"### Overview of Results\nWith the publication of interim consolidated results and full-year forecasts, revenue is expected to be 4,550 hundred million yen (down 11.8% year-over-year), core operating income is expected to be 1,240 hundred million yen (down 9.6% year-over-year), and core net income is expected to be 930 hundred million yen (down 10.1% year-over-year). Primary factors include anticipated decreases in domestic and overseas product sales and the impact of the termination of co-promotion agreements, while royalties and other income are expected to increase. Research and development investment will continue to be actively pursued.\n\n### Business and Investment Trends and Outlook\nTo offset the decrease in product sales, an increase in royalty income is anticipated, and total revenue is forecast at 4,550 hundred million yen. To limit declines in core metrics, the company plans to continue R&D investment while strengthening cost management. The number of employees in the interim period is 4,206 (interim basis), and year-end staffing trends will be monitored.","jir_financial_highlights":"Revenue: 4,550 (Down 11.8% YoY)\nCore Operating Income: 1,240 (Down 9.6% YoY)\nCore Net Income Attributable to Owners of Parent: 930 (Down 10.1% YoY)\nNumber of Employees at Period End: 4,206 (Year-over-year Unknown)","jir_category":"","jir_hashtags":"#OnoPharmaceutical, #Earnings, #InterimResults, #CoreBasisResults","jir_key_figures":"Revenue: 4,550 hundred million yen (Down 11.8% YoY)\nCore Operating Income: 1,240 hundred million yen (Down 9.6% YoY)\nCore Net Income Attributable to Owners of Parent: 930 hundred million yen (Down 10.1% YoY)","jir_meta_title":"Ono Pharmaceutical Co., Ltd. Interim Results (FY ending March 2027) | Revenue 4,550 hundred million yen, Profit Expected to Decline","jir_meta_description":"Summary of Ono Pharmaceutical Co., Ltd.'s interim consolidated results for the fiscal year ending March 2027. Revenue: 4,550 hundred million yen (down 11.8% YoY); Core Operating Income: 1,240 hundred million yen; Core Net Income: 930 hundred million yen. Explains key factors and future investment policy.","jir_og_title":"Ono Pharmaceutical Co., Ltd. | Interim Results and Outlook","jir_og_description":"Interim consolidated results for the fiscal year ending March 2027 for Ono Pharmaceutical Co., Ltd. Revenue is 4,550 hundred million yen, core operating income is 1,240 hundred million yen, with expected contribution from royalties. The company will continue active R&D investment.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7530,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-135980","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n